4th Quarter - Report

WILLIAMS AND JENSEN, PLLC for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

General education about FDA approval policies and NIH research activities. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.

LobbyistCovered position, as disclosed
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals, including S. 586, the NOPAIN Act.

LobbyistCovered position, as disclosed
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 586 (117th)

Taxation/Internal Revenue Code TAX

Orphan drug tax credit issues and general business tax issues.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis
CHERYL LYNN JAEGER Shd employee, Ofc of the Speaker 7 Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. General education about policies to improve health care outcomes for sickle cell disease. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.

LobbyistCovered position, as disclosed
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

General education about policies to improve health care outcomes for sickle cell disease. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to pharmaceuticals.

LobbyistCovered position, as disclosed
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.